Search by Medical Condition
A B C D E F G H I J K L M N O P Q R S T U V W X Y ZClinical Trials for Wet Macular Degeneration
- Safety and Efficacy of RRG001 Gene Therapy in Subjects With Neovascular Age-related Macular Degeneration (nAMD)
- Study to Evaluate the Safety of CG-P5 Peptide Eye Drops in Patients Diagnosed With Age-related Wet Macular Degeneration
- Study to Assess the Efficacy & Safety of KHK4951 in Patients With Neovascular Age-Related Macular Degeneration
- Study to Evaluate an 8 mg Aflibercept (EYLEA®) Prefilled Syringe (PFS)
- A Study to Evaluate the Efficacy and Safety of IBI302 in Subjects With nAMD
- A 2-part Study Consisting of Multiple Ascending Dose (MAD) Safety Study, and a Dose-finding Masked Study to Assess the Safety and Efficacy of Intravitreal (IVT) EYE103 in Patients With Diabetic Macular Edema (DME) or Neovascular Age-related Macular
- Safety and Tolerability of OCU-10-C-110 for Injection in Subjects With Neovascular Age-related Macular Degeneration
- Study to Evaluate Suprachoroidally Administered CLS-AX in the Treatment of Neovascular Age-Related Macular Degeneration
- Safety and Bioactivity of AXT107 in Subjects With Neovascular Age-Related Macular Degeneration (nAMD)
- Study of AR-14034 in Participants With Neovascular Age-Related Macular Degeneration (nAMD)
- Effect of AIV007 by Periocular Administration in Subjects With nAMD or DME
- A Randomized, Double Masked, Parallel Group, Dose-finding Study to Evaluate SYL1801 in Patients With Neovascular Age-related Macular Degeneration (AMD)
- Associations Between the Oral and Intestinal Icrobiome and Neovascular Age-related Macular Degeneration
- A Study Of The Efficacy, Safety, And Pharmacokinetics Of The Port Delivery System With Ranibizumab In Chinese Patients With Neovascular Age-Related Macular Degeneration
- Efficacy and Safety of Intravitreal Conbercept With Modified Treat-and-Extend Regimens in Exudative AMD
- TAB014 Compared to Lucentis® in Patients With Neovascular Age-related Macular Degeneration
- A Study of Longer Interval of IVT IBI302 in Subjects With nAMD
- Study of the Safety of Use of Intravitreal SOK583A1 Provided in a Vial Kit
- Safety, Tolerability, and Efficacy Study of UBX1325 in Patients With Neovascular Age-Related Macular Degeneration (AMD)
- Study of the Safety of Use of Intravitreal SOK583A1 Provided in a Prefilled Syringe
- A Study Of The Effectiveness And Safety Of A 36-Week Refill Regimen For The Port Delivery System With Ranibizumab Vs Aflibercept Treat & Extend In Subjects With Neovascular Age-Related Macular Degeneration
- A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of D-4517.2 After Subcutaneous Administration in Healthy Participants
- Treatment of Neovascular AMD: Artificial Intelligence in Real-world Setting
- Study Evaluating the Treatment of OTX-TKI for Subjects With Neovascular Age-related Macular Degeneration
- A Study Of The Efficacy And Safety Of The Port Delivery System With Ranibizumab In Patients With Neovascular Age-Related Macular Degeneration Previously Treated With Intravitreal Agents Other Than Ranibizumab
- A Study of IBI302 in Patients With nAMD
- A Study to Evaluate the Long-Term Safety and Tolerability of Faricimab in Participants With Neovascular Age-Related Macular Degeneration
- Study of Innovative Multimodal Imaging Biomarkers to Predict Anatomical Outcome in Naive Patients With wAMD Treated With Brolucizumab.
- Safety and Bioactivity of AXT107 in Subjects With Neovascular Age-Related Macular Degeneration
- Brolucizumab vs. Aflibercept for Retinal Angiomatous Proliferation
- Efficacy and Safety of Brolucizumab 6mg in a Treat and Extend Regimen in Patients With Neovascular Age-Related Macular Degeneration (nAMD) With Prior Anti-VEGF Exposure (PEREGRINE)
- Study to Compare Efficacy and Safety of LUBT010 and Lucentis® in Patients With Neovascular AMD
- A Multiple Dose Study of Repeat Intravitreal Injections of GEM103 in Neovascular Age-related Macular Degeneration
- Vitrectomy, Subretinal Tissue Plasminogen Activator (TPA) and Intravitreal Gas for Submacular Haemorrhage Secondary to Exudative (Wet) Age-related Macular Degeneration (TIGER).
- A Study of the Efficacy, Safety, and Pharmacokinetics of A 36-Week Refill Regimen for the Port Delivery System With Ranibizumab in Patients With Neovascular Age-Related Macular Degeneration (Velodrome)
- Safety and Tolerability Study of Suprachoroidal Injection of CLS-AX Following Anti-VEGF Therapy in Neovascular AMD
- An Extension Study Assessing the Efficacy and Safety of Brolucizumab in a Treat-to-Control Regimen in Patients With Neovascular Age-related Macular Degeneration Who Have Completed the CRTH258A2303 (TALON) Study
- Safety and Tolerability Study of UBX1325 in Patients With Diabetic Macular Edema or Neovascular Age-Related Macular Degeneration
- Efficacy and Safety of the Aflibercept FYB203 Biosimilar in Comparison to Eylea® in Patients With Neovascular Age-Related Macular Degeneration
- RGX-314 Gene Therapy Administered in the Suprachoroidal Space for Participants With Neovascular Age-Related Macular Degeneration (nAMD)
- MMP-9 Inhibition for Recalcitrant Wet AMD
- A Study to Comparing SCD411 and Eylea® in Subjects With Wet Age-related Macular Degeneration (AMD)
- A Study to Compare SB15 (Proposed Aflibercept Biosimilar) to Eylea in Subjects With Neovascular Age-related Macular Degeneration (AMD)
- Study to Gather Information on Safety and Use of High Dose Aflibercept Injection Into the Eye in Patients With an Age Related Eye Disorder That Causes Blurred Vision or a Blind Spot Due to Abnormal Blood Vessels That Leak Fluid Into the Light Sensit
- Effect of Intravitreally Administered AIV007 in Subjects With nAMD
- Trial to Evaluate the Safety and Tolerability of Repeated Intravitreal Injection of IBI302 in Neovascular AMD Patients
- A Study to Assess the Efficacy and Safety of AKST4290 With Aflibercept in Patients With Newly Diagnosed nAMD
- Zoledronic Acid as Adjuvant Therapy in Neovascular Age-related Macular Degeneration (Z-AMD)
- Intravitreal Brolucizumab in Neovascular Age-related Macular Degeneration With Limited Response to Aflibercept
- Study of Brolucizumab in Adult Patients With Suboptimal Anatomically Controlled Neovascular Age-related Macular Degeneration
- A Study to Assess the Effects of Brolucizumab in Adult Patients With Neovascular Age Related Macular Degeneration
- The Sahlgrenska Anti-VEGF Study
- Optical Coherence Tomography Angiography (OCTA) - Directed PDT Triple Therapy
- A Study to Evaluate the Efficacy and Safety of KSI-301, an Anti-VEGF Antibody Biopolymer Conjugate, Versus Aflibercept in Patients With Neovascular (Wet) Age-Related Macular Degeneration.
- Study of Efficacy and Safety of Brolucizumab vs. Aflibercept in Chinese Patients With Neovascular Age-Related Macular Degeneration
- A Depot Formulation of Sunitinib Malate (GB-102) Compared to Aflibercept in Subjects With Wet AMD
- Management of Patients With Neovascular Age-related Macular Degeneration Undergoing Cataract Surgery
- Study of the Safety of Brolucizumab 6 mg in Prefilled Syringe in Patients With Neovascular Age Related Macular Degeneration
- Post Intravitreal Injection Topical NSAID vs. Patching
- A Study to Test Different Doses of BI 836880 in Patients With an Eye Disease Called Wet Age-related Macular Degeneration (wAMD)
- A Study Assessing AR-13503 Implant in Subjects With nAMD or DME
- A Study to Evaluate the Efficacy and Safety of Faricimab in Participants With Neovascular Age-Related Macular Degeneration (LUCERNE)
- A Study to Evaluate the Efficacy and Safety of Faricimab in Participants With Neovascular Age-Related Macular Degeneration (TENAYA)
- A Dose Escalation Study of IBI302 in Patients With Wet Age-related Macular Degeneration
- Adjuvant Anti-Mineralocorticoid-Receptor Treatment in Anti-VEGF Refractory Neovascular Age-Related Macular Degeneration
- Extension Study for the Port Delivery System With Ranibizumab (Portal)
- A Phase III Study to Evaluate the Port Delivery System With Ranibizumab Compared With Monthly Ranibizumab Injections in Participants With Wet Age-Related Macular Degeneration
- RBM-007 in Subjects witH ExudatIve Age-related Macular Degeneration
- CLN-0046: Treatment of AMD Subjects With OTX-TKI
- Intense Treatment Regimen With Intravitreal Aflibercept Injection
- Single or Combined Protocols for NV-AMD
- A Study to Evaluate Abicipar Pegol for Safety and Treatment Effect in Participants With Neovascular Age-related Macular Degeneration (AMD)
- Study of PAN-90806 Eye Drops, Suspension for Neovascular AMD
- Two-week Retreatment Interval Study for Treated Age-related Macular Degeneration Refractory to Monthly Aflibercept
- Pegcetacoplan (APL-2) in Neovascular AMD
- Ziv-aflibercept Efficacy in Better Regulating AMD
- A Study of Single Intravitreal Injection HB002.1M in Subjects With Neovascular Age-Related Macular Degeneration
- Study of Safety and Efficacy of Brolucizumab 6 mg Drug Product Intended for Commercialization in Patients With nAMD
- ZIMURA in Combination With LUCENTIS in Patients With Neovascular Age Related Macular Degeneration (NVAMD)
- A Depot Formulation of Sunitinib Malate (GB-102) in Subjects With Neovascular (Wet) Age-related Macular Degeneration
- Safety and Efficacy of AS101 1% Oral Solution in Patients With Neovascular Age-Related Macular Degeneration (AMD)
- Intravitreal Aflibercept for Submacular Hemorrhage
- A Study to Compare SB11 (Proposed Ranibizumab Biosimilar) to Lucentis in Subjects With Neovascular Age-related Macular Degeneration (AMD)
- Efficacy of Biweekly Ranibizumab (0.5 mg) for Exudative Macular Degeneration Retinal Edema Refractory to Anti-VEGF
- Study to Evaluate Faricimab (RO6867461; RG7716) for Extended Durability in the Treatment of Neovascular Age Related Macular Degeneration
- Dorzolamide-timolol in Combination With Anti-vascular Endothelial Growth Factor Injections for Wet Age-related Macular Degeneration
- The IAI-OCTA Study; a Study of OCT-Angiography Analysis Efficacy
- A Study of Multiple Intravitreal Injection TK001 in Patients With Neovascular Age-related Macular Degeneration
- Intraocular Cytokine in Recurrence of Polypoidal Choroidal Vasculopathy
- Efficacy of Fixed Monthly Dosing of Ranibizumab in Neovascular Age-related Macular Degeneration
- Safety and Exploratory Efficacy Study of SF0166 in the Treatment of Neovascular Age-Related Macular Degeneration (AMD)
- A Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamic Activity of Intravitreal LKA651 in Patients With Macular Edema
- Functional and Structural Outcomes in Neovascular Age-related Macular Degeneration
- Prospective Observational Study to Assess Effectiveness of Intravitreal Aflibercept in Patients With Wet Macular Degeneration in Greece
- Safety and Efficacy of Two Regimens of Ranibizumab 0.5 mg in Chinese Patients With Neovascular AMD
- Intravitreal Ranibizumab and TA Combination Therapy vs. Ranibizumab Monotherapy in Polypoidal Choroidal Vasculopathy
- Sirolimus in Conjunction With Eylea vs Eylea Alone for Exudative AMD
- Anti-angiOpoeitin 2 Plus Anti-vascular eNdothelial Growth Factor as a therapY for Neovascular Age Related Macular Degeneration: Evaluation of a fiXed Combination Intravitreal Injection
- A Study in Patients With Neovascular Age Related Macular Degeneration or Macular Edema Secondary To Retinal Vein Occlusion to Evaluate Usability of the Ranibizumab (Lucentis®) Prefilled Syringe (PFS)
- EAGLE: Evaluating Genotypes Using Intravitreal Aflibercept Injection
- PRedictive Factors and Changes From Treatment in iPCV Versus CSR Versus nAMD With afLibercept
- An Open-Label Investigator Sponsored Trial to Investigate the Safety, Tolerability and Development of Subfoveal Fibrosis By Intravitreal Administration of Altering Regimens of Fovista and Anti-VEGF Therapy in Subjects With Neovascular Age-Related Ma
- Managing Neovascular (Known as "Wet") Age-related Macular Degeneration Over 2 Years Using Different Treatment Schedules of 2 mg Intravitreal Aflibercept Injected in the Eye
- Dorzolamide-timolol Drops With Injections to Treat AMD, RVO or DME.
- A Phase I/II Safety, Tolerability, Immunogenicity, and Bioactivity Study of DE-122 Injectable Solution for Refractory Exudative Age-related Macular Degeneration
- Caregiver Burden of Wet Age-related Macular Degeneration (wAMD) in Japan
- Efficacy and Safety of Two Different Aflibercept Regimens in Subjects With Neovascular Age-related Macular Degeneration (nAMD)
- To Describe the Use of Intravitreal Aflibercept and to Describe Follow-up as Well as Treatment Patterns in Patients With Wet Age-related Macular Degeneration (wAMD) or Diabetic Macular Edema (DME) in Routine Clinical Practice in Canada.
- Study of DS-7080a for the Treatment of Macular Degeneration
- Effect of Squalamine Lactate Ophthalmic Solution, 0.2% in Subjects With Neovascular Age-Related Macular Degeneration
- Study of the Efficacy and Safety of the Ranibizumab Port Delivery System for Sustained Delivery of Ranibizumab in Patients With Subfoveal Neovascular Age-Related Macular Degeneration
- Safety and Pharmacokinetics of RTH258 in Subjects With Age-Related Macular Degeneration
- A Safety and Efficacy Study of Abicipar Pegol in Participants With Neovascular Age-related Macular Degeneration
- Safety and Efficacy of Abicipar Pegol in Participants With Neovascular Age-related Macular Degeneration
- Assessment of Safety, Tolerability and Pharmacokinetics of Intravitreal Pegcetacoplan (APL-2) for Patients With Wet AMD
- Adjunctive Photodynamic Therapy + Aflibercept vs. Afilbercept Alone for PDA in NV AMD
- Evaluation the Pharmacokinetics, Safety, Tolerability of BCD-021 in Patients With Neovascular Age-related Macular Degeneration
- Efficacy and Safety of RTH258 Versus Aflibercept - Study 2
- Study of Intravitreal REGN2176-3 in Participants With Neovascular ("Wet") Age-Related Macular Degeneration (AMD)
- LHA510 Proof-of-Concept Study as a Maintenance Therapy for Patients With Wet Age-Related Macular Degeneration
- X-82 to Treat Age-related Macular Degeneration
- Evaluation of the Simplified Treat And Extend Regimen Using Ranibizumab in Exudative Age Related Macular Degeneration
- Evaluation of the Usefulness of a Treat and Extend Regimen Using Ranibizumab for Neovascular AMD.
- Real Life of Aflibercept in France in Patients Refractory to Ranibizumab: Observational Study in Wet AMD
- Intravitreal Aflibercept in Neovascular AMD With Limited Response to Ranibizumab
- Efficacy and Safety of RTH258 Versus Aflibercept - Study 1
- Japanese Treat and Extend Study of Aflibercept in Neovascular Age-related Macular Degeneration
- Aflibercept (Eylea) in roUtine Clinical Practice in patientS With Wet Age-related Macular Degeneration in Italy
- Real Life of Aflibercept In FraNce: oBservatiOnnal Study in Wet AMD
- Regorafenib Eye Drops: Investigation of Efficacy and Safety in Neovascular Age Related Macular Degeneration
- A Pharmacokinetic Study of Intravitreal Aflibercept Injection in Vitrectomized and Non-vitrectomized Eyes With Wet Age-related Macular Degeneration (DRAW).
- Safety and Efficacy of Switching From Aflibercept to Ranibizumab in Patients With nAMD
- Aflibercept After Ranibizumab in Exudative Age-related Macular Degeneration
- Prophylactic Ranibizumab for Exudative Age-related Macular Degeneration
- Plasma Levels of Vascular Endothelial Growth Factor Before and After Intravitreal Injection of Aflibercept
- A 4 Week Study With BI 144807 in Patients >= 50 Years With Wet Age Related Macular Degeneration
- Aflibercept in Polypoidal Choroidal Vasculopathy
- Pilot Study of Ranibizumab With and Without Ketorolac Eyedrops for Exudative Age-related Macular Degeneration
- Phase 1 Study of Topical Ocular PAN-90806 for Neovascular AMD
- Study of Intravitreal (IVT) REGN910-3 and IVT REGN910 in Patients With Either Neovascular ("Wet") Age Related Macular Degeneration (AMD) or Diabetic Macular Edema (DME)
- Treat and Extend Therapy Study Using Intravitreal Aflibercept for Patients Exited From Protocol VGFT-OD 0910
- Effect of Intravitreal VEGF-Trap Eye on Polypoidal Choroidal Vasculopathy
- Evaluation of Pain and Inflammation After Injection of Lucentis vs Eylea for Treatment of Wet Macular Degeneration
- Aflibercept (EYLEA)as Secondary or Third Line Treatment for Neovascular Age-related Macular Degeneration.
- Study to Evaluate Efficacy of Aflibercept in Neovascular Age-related Macular Degeneration Patients Non Responders to Anti-Vascular Endothelial Growth Factor
- Impact of Home Monitoring to Decrease the Treatment Burden for Neovascular Age-related Macular Degeneration (AMD)
- ESBA1008 Microvolume Study
- Intravitreal tPA and C3F8 for the Treatment of Submacular Haemorrhage as a Complication of Neovascular AMD
- Indocyanine Angiographic Changes of Choroidal Neovascularization by Ranibizumab
- Efficacy and Safety Study of ESBA1008 Versus EYLEA®
- Efficacy and Safety of Two Treatment Regimens of 0.5 mg Ranibizumab Intravitreal Injections Guided by Functional and/or Anatomical Criteria, in Patients With Neovascular Age-related Macular Degeneration
- Efficacy and Safety of Ranibizumab 0.5 mg Administered as Two Alternative Dosing Regimens in Chinese Patients With nAMD (Age Related Macular Degeneration)
- Study to Assess Best Corrected Visual Acuity (BCVA) in Patients With Neovascular Age-Related Macular Degeneration (AMD) Who Are Administered VEGF Trap-Eye (Intravitreal Aflibercept Injection)
- Efficacy and Safety of Squalamine Lactate Eye Drops in Subjects With Neovascular (Wet) Age-related Macular Degeneration (AMD)
- Pilot Study of X-82 in Patients With Wet AMD
- Safety and Tolerability of Intravenous LFG316 in Wet Age-related Macular Degeneration (AMD).
- Wet Macular Degeneration Study to Compare Ranibizumab or Bevacizumab to Aflibercept
- Combretastatin A4 Phosphate in Patients With Neovascular Age-Related Macular Degeneration
- Safety and Efficacy of Intravitreal LFG316 in Wet Age Related Macular Degeneration (AMD)
- Study of Bimonthly VEGF Trap-Eye Compared to As-needed Administration or Other Therapy for Exudative Age-Related Macular Degeneration
- FUSION Regimen: Combined Pro re Nata and Fixed Regimen Ranibizumab in Exudative Age-related Macular Degeneration
- Safety and Tolerability Study for Age-Related Macular Degeneration
- Analysis of Growth Factors in Patients Undergoing Lucentis or Avastin Injections for Diabetic Macular Edema and Exudative Macular Degeneration
- Non-Persistence/Non-Adherence (NP/NA) in Wet Age-related Macular Degeneration (wAMD) Patients in Germany
- Efficacy and Safety Study of iSONEP With & Without Lucentis/Avastin/Eylea to Treat Wet AMD
- 12 Week Patient Study in Neovascular Age-related Macular Degeneration (AMD)
- iSONEP to Treat Persistent Pigment Epithelial Detachment (PED) in Subjects With Exudative Age-Related Macular Degeneration (AMD) or Polypoidal Choroidal Vasculopathy (PCV)
- Intravitreal Bevacizumab for Low Vision in Neovascular Age-related Macular Degeneration (AMD)
- Bevacizumab for Neovascular Age-related Macular Degeneration
- Palomid 529 in Patients With Neovascular Age-Related Macular Degeneration
- Sub-tenon Triamcinolone Acetonide in Age-Related Macular Degeneration as Adjunct to Ranibizumab
- Observational Study Of The Long-Term Effect Of Macugen In Patients With Wet Age-Related Macular Degeneration
- OZURDEX in Age Related Macular Degeneration as Adjunct to Ranibizumab
- ProspectiveTrial of Proton Beam Combined With Anti-VEGF Therapy for Exudative Age-related Macular Degeneration (AMD)
- HiPED - High Dose Lucentis for Persistent Pigment Epithelial Detachments in Age-related Macular Degeneration
- Evaluation of AL-78898A in Exudative Age-Related Macular Degeneration
- A Study to Evaluate Pazopanib Tablets in Patients Who Have Neovascular Age-related Macular Degeneration
- Dose Ranging Study of Pazopanib to Treat Neovascular Age-Related Macular Degeneration
- LUCAS (Lucentis Compared to Avastin Study)
- A Safety and Efficacy Study of E10030 (Anti-PDGF Pegylated Aptamer) Plus Lucentis for Neovascular Age-Related Macular Degeneration
- Phase I Study of Palomid 529 a Dual TORC1/2 Inhibitor of the PI3K/Akt/mTOR Pathway for Advanced Neovascular Age-Related Macular Degeneration
- Long-term Results After Intravitreal Bevacizumab Treatment Of Neovascular Age-related Macular Degeneration
- A Study of Intravitreal Injections of 2.0mg Ranibizumab in Subjects With Chronic Fluid On OCT Post Multiple Injections With Ranibizumab (Super-dose Anti-VEgf SAVE Trial)
- Study of Intravitreal Microplasmin in Relieving Vitreo-Macular Adhesion in Neovascular Age-related Macular Degeneration
- Combination of Ranibizumab and Verteporfin Therapy in Neovascular Age-related Macular Degeneration
- Open-label Extension Study of Intravitreal Aflibercept Injection (IAI; EYLEA®; BAY86-5321) in Neovascular ("Wet") Age-related Macular Degeneration (AMD)
- Safety and Efficacy Study of Intravitreal Ocriplasmin in Subjects With AMD With Focal Vitreomacular Adhesion
- Supplemental Adjuvants for Intracellular Nutrition and Treatment
- A Study of Ranibizumab Administered Monthly or on an As-needed Basis in Patients With Subfoveal Neovascular Age-related Macular Degeneration (HARBOR)
- Efficacy And Safety Of Macugen In Patients With Neovascular AMD In Routine Clinical Practice.
- The Efficacy of Oral Everolimus in Patients With Neovascular Age-related Macular Degeneration
- Efficacy, Safety, Tolerability of Pegaptanib Sodium (Macugen) in Filipino Patients With Neovascular Age Related Macular Degeneration.
- Combination Ranibizumab and Bromfenac for Neovascular Age-related Macular Degeneration
- A Prospective Study Comparing Ranibizumab Plus Dexamethasone Combination Therapy Versus Ranibizumab Monotherapy for Wet AMD
- Subretinal Macugen® for Neovascular Age-Related Macular Degeneration
- Pilot Study to Evaluate the Safety and Efficacy of Treatment With ORA102 Combined With Avastin (Bevacizumab) Versus Avastin Alone, in Patients With Neovascular Age Related Macular Degeneration (AMD)
- ARC1905 (ANTI-C5 APTAMER) Given Either In Combination Therapy With Lucentis® 0.5 mg/Eye In Subjects With Neovascular Age-Related Macular Degeneration
- Photodynamic Therapy Combined With Bevacizumab vs Bevacizumab Alone for Neovascular Age-Related Macular Degeneration
- The Effects of Bevacizumab and Ranibizumab on Ocular Pulse Amplitude in Neovascular Age Related Macular Degeneration (AMD)
- Vascular Endothelial Growth Factor (VEGF) Trap-Eye: Investigation of Efficacy and Safety in Wet Age-Related Macular Degeneration (AMD)
- Lucentis for Age-related Macular Degeneration Pigment Epithelial Detachments
- Efficacy and Safety Study of Lucentis (Ranibizumab) and Visudyne (Verteporfin) Combination Therapy in Neovascular AMD
- A Phase 1, Safety, Tolerability and Pharmacokinetic Profile of Intravitreous Injections of E10030 (Anti-PDGF Pegylated Aptamer) in Subjects With Neovascular Age-Related Macular Degeneration
- Prevention of Vision Loss in Patients With Age-Related Macular Degeneration (AMD) by Intravitreal Injection of Bevacizumab and Ranibizumab
- A Study On The Efficacy Of Macugen Injections In Patients With Neovascular Age-Related Macular Degeneration In Real Life.
- Randomized, Single-Masked, Long-Term, Safety and Tolerability Study of VEGF Trap-Eye in AMD
- Pilot Study of Lucentis Combined With Proton Beam Irradiation in Treating Wet Age-related Macular Degeneration
- Safety of Intravitreal POT-4 Therapy for Patients With Neovascular Age-Related Macular Degeneration (AMD)
- Ocular Safety Of Patients Receiving Macugen For Neovascular Age Related Macular Degeneration
- Combination Therapy for Neovascular Age Related Macular Degeneration
- The Avastin vs Visudyne for Neovascular AMD Study
- Safety and Tolerability of Intravitreal VEGF Trap Formulations in Subjects With Neovacular AMD
- An OCT-Guided Variable Dosing Regimen With Ranibizumab for the Treatment of Neovascular AMD
- Combined PDT and Intravitreal Bevacizumab vs Combination of PDT, Intravitreal Bevacizumab and Triamcinolone for Neovascular AMD
- Intravitreal Bevacizumab vs. Bevacizumab Combined With Triamcinolone for Neovascular AMD
- Prospective OCT Study With Lucentis for Neovascular AMD (PrONTO Study)
- An Open Label Trial to Investigate Macugen for the Preservation of Visual Function in Subjects With Neovascular AMD
- Safety and Tolerability Study of Intravitreal VEGF-Trap Administration in Patients With Neovascular AMD
- Neovascular Age Related Macular Degeneration (AMD), Periocular Corticosteroids, and Photodynamic Therapy (PDT)
- Anecortave Acetate in Patients With Exudative Age-related Macular Degeneration (AMD)
- Study of the Safety, Tolerability and Pharmacokinetics of 1 Mg/Eye and 3 Mg/Eye Pegaptanib Sodium in Patients With Exudative Age-Related Macular Degeneration (AMD)
- Study of the Combination of Anecortave Acetate and Triamcinolone Acetonide for the Treatment of Exudative Age-Related Macular Degeneration (AMD)
- Study of AdGVPEDF.11D in Neovascular Age-related Macular Degeneration (AMD)
- Extension Study of rhuFab V2 in Subjects With Neovascular Age-Related Macular Degeneration (AMD)
- Intravitreous Pegaptanib Sodium Injection in Patients With Exudative Age-Related Macular Degeneration (AMD)
- A Study to Compare rhuFab V2 With Verteporfin Photodynamic in Treating Subfoveal Neovascular Macular Degeneration
- A Study to Evaluate rhuFab V2 in Subjects With Minimally Classic or Occult Subfoveal Neovascular Macular Degeneration